Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

Glioblastoma Clinical Trial

— ATTAC-II  

Official title:

ATTAC-II: A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02465268
• Other study ID #: IRB201400697-N
• Secondary ID: R01CA175517OCR14
• Status: Completed
• Phase: Phase 2
• Start date: August 9, 2016
• Est. completion date: November 30, 2023

Study information

• Verified date: March 2024
• Source: University of Florida
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger doses of routine chemotherapy.

Description:

Dendritic cells (DC) are involved in activating, or turning-on, your body's immune system. Your immune system helps guard your body from germs, viruses, and other threats. Although dendritic cells are very strong, the number of them in the body is not high enough to cause a powerful immune response; therefore, more DC are made in a laboratory with cells collected from an individual's blood.

In this study, we will make a vaccine that we hope will educate immune cells to target the pp65 antigen, a type of immune marker in GBM, thus resulting in what we call the pp65 DC vaccine. Use of a vaccine that activates your immune system is a type of immunotherapy. It is hoped that by giving the pp65 DC vaccine as a shot under the skin, the immune system will be activated to attack tumor cells in the brain while leaving normal cells alone.

To see if the pp65 DC vaccine is effective for the treatment of GBM, subjects will be assigned to different treatment groups. Two groups of subjects will receive the pp65 DC vaccine and one group will receive a placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 175
• Est. completion date: November 30, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Abbreviated Inclusion Criteria:

To be assessed at study enrollment prior to standard of care chemo-radiation therapy:

• Age = 18 years.

• Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma)

• The tumor must have a supratentorial component.

• Must have undergone definitive surgical resection of tumor with less than approximately 3cm x 3cm residual enhancing tumor as product of longest perpendicular planes by MRI.

• Recovery from the effects of surgery, postoperative infection, and other complications.

• Diagnostic contrast-enhanced MRI or CT scan of the brain preoperatively and postoperatively.

• Karnofsky Performance Status of = 70.

• Signed informed consent.

• For females of childbearing potential, negative serum pregnancy test.

• Women of childbearing potential and male participants must be willing to practice adequate contraception throughout the study and for at least 24 weeks after the last dose of study drug.

To be assessed prior to initiation of adjuvant TMZ:

• Must have completed RT (targeted total dose of 59.4-60.0 Gy over = 7 weeks) and concomitant TMZ (targeted dose of 75mg/m2/d for = 49 days) therapy without significant toxicity that persisted over 4 weeks.

• History & physical with neurologic examination prior to initiation of adjuvant TMZ.

• For patients receiving steroids, daily dose must be = 4 mg.

• CBC with differential with adequate bone marrow function.

• Adequate renal function.

• Adequate hepatic function.

Abbreviated Exclusion Criteria:

To be verified in order to randomize subject:

• Prior invasive malignancy unless disease free for = 3 years.

• Metastases detected below the tentorium or beyond the cranial vault and leptomeningeal involvement.

• Recurrent or multifocal malignant gliomas.

• HIV, Hepatitis B, or Hepatitis C seropositive.

• Known active infection or immunosuppressive disease.

• Prior chemotherapy or radiosensitizers (including Gliadel wafers) for cancers of the head and neck region.

• Prior radiotherapy to the head or neck, resulting in overlap of radiation fields.

• Severe, active co-morbidity.

• Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period.

• Pregnant or lactating women.

• Prior allergic reaction to temozolomide, GM-CSF or Td.

• Prior history of brachial neuritis or Guillain-Barré syndrome.

• Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry.

To be assessed prior to initiation of adjuvant TMZ:

• Did not start radiation therapy and temozolomide within 7 weeks of surgery.

• Progression of disease as defined by modified RANO criteria.

• More than 45 days after completion of radiation therapy and temozolomide

Related Conditions & MeSH terms

• Astrocytoma
• Astrocytoma, Grade IV
• GBM
• Glioblastoma
• Glioblastoma Multiforme
• Glioma
• Malignant Glioma

Intervention

Biological:
• pp65-shLAMP DC with GM-CSF

• unpulsed PBMC and saline

Drug:
• Td
All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
• Saline

Biological:
• pp65-flLAMP DC with GM-CSF

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina
United States	University of Florida	Gainesville	Florida
United States	Orlando Health	Orlando	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Florida	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in median overall survival		From date of randomization until the date of death, assessed up to 24 months
Secondary	Changes in immune response	Parameters include ELISPOT for evaluation of cellular immune responses is a sensitive detection assay for evaluation of antigen specific cytokine producing T cells	Change between baseline and vaccine #3, assessed up to 4 weeks
Secondary	Change in progression-free survival		From randomization until first documentation of either disease progression or recurrence assessed up to 24 months
Secondary	Changes in immune response	Parameters include peak antibody titers to the CMV pp65, reported as humoral response to the specific antigens.	Change between baseline and vaccine #3, assessed up to 4 weeks
Secondary	Changes in immune response	Parameters include Cytokine Bead Array analysis to detect multiple cytokines secreted by lymphocytes after in vitro stimulation with specific and control antigens, examine the spectrum of Type 0,1,2, and 3 cytokines secreted by T cells after stimulation with overlapping peptides spanning CMV pp65, PHA, and control peptides	Change between baseline and vaccine #3, assessed up to 4 weeks
Secondary	Changes in immune response	Parameters include cytokine flow cytometric analysis which involves the rapid early detection and analysis of the production of IFN, TNF, and IL-2 prior to cellular secretion following antigen-specific stimulation in vitro as determined by CFC	Change between baseline and vaccine #3, assessed up to 4 weeks